{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:57:45Z","timestamp":1763535465017},"reference-count":21,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.3892\/ol.2017.6511","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T11:18:34Z","timestamp":1498821514000},"page":"3035-3038","source":"Crossref","is-referenced-by-count":30,"title":["Lung cancer requires multidisciplinary treatment to improve patient survival: A case report"],"prefix":"10.3892","volume":"14","author":[{"given":"Aldo","family":"Pezzuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Terzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierdonato","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Mariotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"key20180108114257_b1-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2016.0031","article-title":"NCCN guidelines insights: Non-Small cell lung cancer, version 4.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"key20180108114257_b2-ol-0-0-6511","unstructured":"MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc83584594200810.1016\/S0025-6196(11)60735-018452692"},{"key":"key20180108114257_b3-ol-0-0-6511","first-page":"1471","article-title":"Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: A systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2016","journal-title":"Onco Targets Ther"},{"key":"key20180108114257_b4-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180108114257_b5-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000442344","article-title":"The efficacy of single-agent epidermal growth factor receptor tyrosine kinase inhibitor therapy in biologically selected patients with non-small-cell lung cancer: A meta-analysis of 19 randomized controlled trials","volume":"61","author":"Li","year":"2016","journal-title":"Chemotherapy"},{"key":"key20180108114257_b6-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20180108114257_b7-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180108114257_b8-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"key20180108114257_b9-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20180108114257_b10-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108114257_b11-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"key":"key20180108114257_b12-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1378\/chest.112.2.430","article-title":"Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for syntomatic malignant pleural effusions","volume":"112","author":"Zimmer","year":"1997","journal-title":"Chest"},{"key":"key20180108114257_b13-ol-0-0-6511","first-page":"103","article-title":"Non-intubated video-assisted thoracic surgery as the modality of choice for treatment of recurrent pleural effusions","volume":"3","author":"Cox","year":"2015","journal-title":"Ann Transl Med"},{"key":"key20180108114257_b14-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1183\/09031936.06.00013706","article-title":"Thoracoscopy: General overview and place in the diagnosis and management of pleural effusion","volume":"28","author":"Rodriguez-Panadero","year":"2006","journal-title":"Eur Resp J"},{"key":"key20180108114257_b15-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"e87060","DOI":"10.1371\/journal.pone.0087060","article-title":"Efficacy and safety of talc pleurodesis for malignant pleural effusion: A meta-analysis","volume":"9","author":"Xia","year":"2014","journal-title":"PLoS One"},{"key":"key20180108114257_b16-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3322\/caac.21390","article-title":"Lung cancer-major changes in the American Joint Committee on cancer eighth edition cancer staging manual","volume":"67","author":"Rami-Porta","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20180108114257_b17-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13014-016-0693-8","article-title":"A critical review of recent developments in radiotherapy for non-small cell lung cancer","volume":"11","author":"Baker","year":"2016","journal-title":"Radiat Oncol"},{"key":"key20180108114257_b18-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.canrad.2016.01.013","article-title":"Non-small cell lung cancer irradiation in elderly","volume":"20","author":"Dupic","year":"2016","journal-title":"Cancer Radiother"},{"key":"key20180108114257_b19-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180108114257_b20-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: Current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"key20180108114257_b21-ol-0-0-6511","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40261-012-0001-9","article-title":"First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer: Analysis of the Italian patients enrolled in the SAiL study","volume":"32","author":"Bearz","year":"2012","journal-title":"Clin Drug Investig"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T16:45:38Z","timestamp":1515429938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,6,30]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.3892\/ol.2017.6511"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6511","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}